Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis

Autor: Hyung, J., Lee, J.Y., Kim, J.E., Yoon, S., Yoo, C., Hong, Y.S., Jeong, J.H., Kim, T.W., Jeon, S., Jun, H.R., Jung, C.K., Jang, J.P., Kim, J., Chun, S.M., Ahn, J.H.
Zdroj: In ESMO Open June 2023 8(3)
Databáze: ScienceDirect